Forest earnings drop on higher costs

Forest Laboratories ($FRX) posted a drop in fiscal second-quarter earnings on higher costs, but sales rose 9%, thanks to strong early sales of two new products. But revenue still depends heavily on two older products, Lexapro and Namenda, that are on the verge of losing patent protection, and analysts wonder whether Forest's new drugs are novel enough to capture sizable market share. Report | News

Suggested Articles

In a trial called Empacta, Roche's IL-6 inhibitor cut ventilator use, but didn't significantly cut the risk of death in COVID-19 pneumonia patients.

Officials in New York charged Johnson & Johnson with violating insurance laws with its opioid marketing.

Regeneron and Sanofi hope their PD-1 inhibitor Libtayo will be the first immuno-oncology treatment approved to treat basal cell carcinoma.